Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 27, 2011 Michael Olsen	Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment.
The Motley Fool July 22, 2009 Robert Steyer	Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry.
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool August 1, 2008 Brian Orelli	Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
Pharmaceutical Executive June 1, 2013	When Gurus Get It Wrong Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell.
The Motley Fool July 30, 2004 Chris Mallon	Adjusting for Innovation If research and development is an investment, why not treat it as such? While not necessarily cheap, tech companies don't appear quite so overvalued when you adjust for investment in innovation.
The Motley Fool October 29, 2009 Robert Steyer	Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle.
The Motley Fool April 20, 2011 Brandon Glenn	Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle.
Chemistry World October 26, 2011 Maria Burke	Europe risks being outstripped by R&D rivals EU companies are lagging behind in R&D investment compared with major competitors from the US and some Asian economies, according to the European Commission's 2011 EU Industrial R&D Investment Scoreboard.
The Motley Fool January 10, 2006 Stephen D. Simpson	Can ICON Be a Paragon of Growth? The clinical research organization specialist and stock have recovered from some troubles, but do current valuations leave much on the table?
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
IndustryWeek May 1, 2008 John Teresko	Metrics Matter The top R&D metric used in 2008 is R&D spending as a percentage of sales.
IndustryWeek December 1, 2007 Jill Jusko	Hey Big Spender: By the Numbers A look at R & D spending in 2006.
Pharmaceutical Executive May 1, 2007	Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge.
The Motley Fool February 4, 2008 Chuck Saletta	Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker.
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
IEEE Spectrum December 2007 Hira & Ross	The R&D 100 A company's research budget tells you very little about its prospects.
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
Chemistry World March 25, 2015 Dennis Lendrem	Be careful what you wish for There is a big debate right now in the pharmaceutical industry, and specifically about measuring R&D productivity. It all comes down to a choice of metrics.
The Motley Fool October 26, 2011 Brian Stoffel	5 Stocks Our Experts Are Buying Now An update on our Rising Star portfolios, with five of the most recent buys by our analysts, along with the thesis behind their purchases.
Pharmaceutical Executive April 1, 2009 David Zuckerman	Make a Match Big Pharma is finally making a commitment to partner-based outsourcing.
The Motley Fool March 15, 2004 Ben McClure	More R&D, Please Big tech players up the research and development ante.
The Motley Fool April 19, 2004 Ben McClure	Ruminations on R&D Spending on research and development is important. But can it help identify promising investments? It's pretty easy to spot companies that spend a lot of money on R&D. It's another thing to pick companies that translate R&D spending into higher stock prices.
PC Magazine January 10, 2007 Sarah Pike	Invisible Icon Close system applications using the icon in the upper left corner of Windows.
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
IEEE Spectrum December 2005 Hira & Goldstein	R&D 100 Automakers top the list, drug companies trim back, and telecoms continue to gut their research budgets.
The Motley Fool March 15, 2007 Chuck Saletta	The American Century Is Over As more R&D takes place overseas, the technological advances and profits will follow. So should investors.
IndustryWeek June 23, 2010	By The Numbers -- The Expense of R&D Among U.S.-owned businesses and U.S. affiliates of foreign companies, much of the R&D remained in the United States.
IndustryWeek November 3, 2009	Benchmarking R&D Top innovators increased their research-and-development spending even as the economy sank, according to the Booz & Co. fifth annual analysis of global innovation spending.
Chemistry World May 8, 2012 Helen Carmichael	Pharma firms see mixed fortunes in Quebec Quebec's life sciences and pharmaceutical industry has suffered several blows in 2012, with hundreds of R&D jobs being lost. This comes despite the industry receiving hundreds of millions of dollars in government assistance and favorable tax rates.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
The Motley Fool January 19, 2006 Stephen D. Simpson	Pfizer: Less Bad Is Good Enough Pfizer's quarter wasn't strong, but it was better than expected. The company may not be able to recapture past glories, but the stock is still good idea for long-term.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
Chemistry World December 21, 2015 Phillip Broadwith	Is bigger really better? Something that's often glossed over in the aftermath of a pharmaceutical mega-merger is whether savings actually materialize, and at what cost to the future success of the businesses.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
Pharmaceutical Executive June 1, 2005 Jan Malek	When Two Heads are Better R&D president isn't one job-it's two. By appointing COOs for R&D with broad operational mandates, biotech and pharmaceutical companies can ensure that operational issues get the attention they urgently require.
IndustryWeek April 1, 2009 Jill Jusko	Flat Forecast for R&D Spending: By The Numbers Companies will shift their focus to new business versus existing business or basic research in 2009.
The Motley Fool September 23, 2011 Michael Olsen	1 Special Stock Pick From an Outside View Don't fall prey to market myopia. We expect contract researchers -- like Charles River, Icon, and Pharmaceutical Product Development -- to benefit as pharmaceutical companies adopt an increasingly cost-conscious posture.
Information Today August 11, 2015	Thomson Reuters Rolls Out Pharmaceutical R&D Factbook The 2015 CMR International Pharmaceutical R&D Factbook shows global R&D trends for the biopharmaceutical industry.
Pharmaceutical Executive September 1, 2012 Roy F. Waldron	Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector?
The Motley Fool November 30, 2007 Brian Orelli	Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way.
The Motley Fool June 6, 2006 Rich Smith	Foolish Forecast: H&R's Reality Block With the books finally closed on fiscal fourth-quarter, the nation's leading paid tax preparer, H&R Block, reports on the tax season (and full fiscal year) that was tomorrow. Want to know what Wall Street expects to see? Want to know what really matters?
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.